The Dr. Doug Show Can This New Compound, AP503, Actually Reverse Bone Loss? (Doctor Explains)
4 snips
Oct 27, 2025 Join Dr. Doug Lucas as he explores the potential of AP503, a novel compound aimed at boosting bone health by targeting the GPR133 receptor. Early studies show promise in preventing menopause-related bone loss. However, he emphasizes the importance of proven strategies like strength training, nutrition, and hormone optimization. Get insights into the drug development timeline and why immediate action is vital for bone health. Plus, learn how hormones like DHEA and testosterone play a significant role in maintaining strong bones.
AI Snips
Chapters
Transcript
Episode notes
GPR133 Is A Bone-Building Switch
- GPR133 is a receptor on osteoblasts that increases bone-building when activated.
- AP503 targets GPR133 and made bones thicker and stronger in mice, including menopause models.
Exercise Activates The Same Pathway
- GPR133 responds to mechanical stress, so exercise naturally stimulates the same pathway as AP503.
- Combining AP503-like activation with exercise could amplify bone benefits beyond either alone.
Don’t Wait — Timeline Is Years
- Expect a long timeline: AP503 is in animal studies and human trials could take a decade or more.
- Do not rely on AP503 now; continue using proven bone-health strategies available today.